Chronic treatment of astrocytes with therapeutically relevant fluoxetine concentrations enhances cPLA2 expression secondary to 5-HT2B-induced, transactivation-mediated ERK1/2 phosphorylation - PubMed (original) (raw)
Chronic treatment of astrocytes with therapeutically relevant fluoxetine concentrations enhances cPLA2 expression secondary to 5-HT2B-induced, transactivation-mediated ERK1/2 phosphorylation
Baoman Li et al. Psychopharmacology (Berl). 2009 Nov.
Abstract
Introduction: We have recently shown that fluoxetine, a serotonin-specific reuptake inhibitor (SSRI), has low micromolar affinity for the 5-HT(2C) receptor (but not for 5-HT(2A) and 5-HT(2B) receptors) in primary cultures of mouse astrocytes. This was determined as phosphorylation (stimulation) of extracellular-regulated kinase 1 and 2 (ERK(1/2)) by transactivation-mediated phosphorylation of the epidermal growth factor (EGF) receptor, followed by conventional EGF receptor signaling (Li et al., Psychopharmacology 194:333-334, 2007). Paroxetine has an identical effect. The present study shows that chronic fluoxetine treatment with even higher affinity (EC(50) = 0.5-2.0 microM) upregulates Ca(2+)-dependent phospholipase A(2) (cPLA(2)), which releases arachidonic acid from the sn-2 position of membrane-bound phospholipid, without effect on secretory PLA(2) (sPLA(2)) and intracellular PLA(2) (iPLA(2)).
Discussion: This demonstration replicates the fluoxetine-induced cPLA(2) upregulation in rat brain shown by Rao et al. (Pharmacogenomics J 6:413-420, 2006) and provides the new information that upregulation (1) occurs in astrocytes, (2) is evoked by stimulation of 5-HT(2B) receptor, and (3) requires transactivation-mediated ERK(1/2) phosphorylation. Similar upregulation of cPLA(2) in intact brain in response to 5-HT(2)-mediated signaling by elevated serotonin levels and/or an SSRI during antidepressant treatment may explain the repeatedly reported ability of SSRIs to normalize regional decreases which occur in brain metabolism during major depression, since (1) arachidonic acid strongly stimulates glucose metabolism in cultured astrocytes (Yu et al., J Neurosci Res 64:295-303, 1993) and (2) plasma concentrations of arachidonic acid in depressed patients are linearly correlated with regional brain glucose metabolism (Elizabeth Sublette et al., Prostaglandins Leukot Essent Fatty Acids 80:57-64, 2009).
Similar articles
- 5-HT2B receptors are expressed on astrocytes from brain and in culture and are a chronic target for all five conventional 'serotonin-specific reuptake inhibitors'.
Zhang S, Li B, Lovatt D, Xu J, Song D, Goldman SA, Nedergaard M, Hertz L, Peng L. Zhang S, et al. Neuron Glia Biol. 2010 May;6(2):113-25. doi: 10.1017/S1740925X10000141. Epub 2010 Sep 16. Neuron Glia Biol. 2010. PMID: 20846463 - Fluoxetine-mediated 5-HT2B receptor stimulation in astrocytes causes EGF receptor transactivation and ERK phosphorylation.
Li B, Zhang S, Zhang H, Nu W, Cai L, Hertz L, Peng L. Li B, et al. Psychopharmacology (Berl). 2008 Dec;201(3):443-58. doi: 10.1007/s00213-008-1306-5. Epub 2008 Aug 29. Psychopharmacology (Berl). 2008. PMID: 18758753 - Serotonin increases ERK1/2 phosphorylation in astrocytes by stimulation of 5-HT2B and 5-HT2C receptors.
Li B, Zhang S, Li M, Hertz L, Peng L. Li B, et al. Neurochem Int. 2010 Nov;57(4):432-9. doi: 10.1016/j.neuint.2010.04.017. Epub 2010 May 5. Neurochem Int. 2010. PMID: 20450948 - Astrocytic 5-HT(2B) receptor as in vitro and in vivo target of SSRIs.
Peng L, Huang J. Peng L, et al. Recent Pat CNS Drug Discov. 2012 Dec;7(3):243-53. doi: 10.2174/157488912803252078. Recent Pat CNS Drug Discov. 2012. PMID: 22963281 Review. - Astrocytic transactivation by alpha2A-adrenergic and 5-HT2B serotonergic signaling.
Peng L, Li B, Du T, Kong EK, Hu X, Zhang S, Shan X, Zhang M. Peng L, et al. Neurochem Int. 2010 Nov;57(4):421-31. doi: 10.1016/j.neuint.2010.04.018. Epub 2010 May 5. Neurochem Int. 2010. PMID: 20450946 Review.
Cited by
- Pharmacometabolomic mapping of early biochemical changes induced by sertraline and placebo.
Kaddurah-Daouk R, Bogdanov MB, Wikoff WR, Zhu H, Boyle SH, Churchill E, Wang Z, Rush AJ, Krishnan RR, Pickering E, Delnomdedieu M, Fiehn O. Kaddurah-Daouk R, et al. Transl Psychiatry. 2013 Jan 22;3(1):e223. doi: 10.1038/tp.2012.142. Transl Psychiatry. 2013. PMID: 23340506 Free PMC article. Clinical Trial. - Biphasic Regulation of Caveolin-1 Gene Expression by Fluoxetine in Astrocytes: Opposite Effects of PI3K/AKT and MAPK/ERK Signaling Pathways on c-fos.
Li B, Jia S, Yue T, Yang L, Huang C, Verkhratsky A, Peng L. Li B, et al. Front Cell Neurosci. 2017 Oct 31;11:335. doi: 10.3389/fncel.2017.00335. eCollection 2017. Front Cell Neurosci. 2017. PMID: 29163047 Free PMC article. - Cell type-specific in vivo expression of genes encoding signalling molecules in the brain in response to chronic mild stress and chronic treatment with fluoxetine.
Dong L, Li B, Verkhratsky A, Peng L. Dong L, et al. Psychopharmacology (Berl). 2015 Aug;232(15):2827-35. doi: 10.1007/s00213-015-3921-2. Epub 2015 Apr 9. Psychopharmacology (Berl). 2015. PMID: 25851944 - Astroglial Serotonin Receptors as the Central Target of Classic Antidepressants.
Verkhratsky A, Parpura V, Scuderi C, Li B. Verkhratsky A, et al. Adv Neurobiol. 2021;26:317-347. doi: 10.1007/978-3-030-77375-5_13. Adv Neurobiol. 2021. PMID: 34888840 Free PMC article. - Major depressive disorder: hypothesis, mechanism, prevention and treatment.
Cui L, Li S, Wang S, Wu X, Liu Y, Yu W, Wang Y, Tang Y, Xia M, Li B. Cui L, et al. Signal Transduct Target Ther. 2024 Feb 9;9(1):30. doi: 10.1038/s41392-024-01738-y. Signal Transduct Target Ther. 2024. PMID: 38331979 Free PMC article. Review.
References
- Brain Res Dev Brain Res. 1991 Nov 19;63(1-2):33-41 - PubMed
- Eur J Pharmacol. 2008 Feb 12;580(3):350-4 - PubMed
- Biol Psychiatry. 1997 Jan 1;41(1):15-22 - PubMed
- Neuropsychopharmacology. 2005 Aug;30(8):1576-83 - PubMed
- Eur J Pharmacol. 2001 Feb 23;414(1):23-30 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous